Disclosure Of Interests In Other Entities [Text Block]

Xbrane Biopharma - Filing #679208

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Disclosure of interests in other entities [text block]	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Profit (loss), attributable to non-controlling interests	—	—	– SEK	—	—	—	—	—	– SEK	—	—	—	—
Non-controlling interests	—	—	—	– SEK	—	—	– SEK	—	—	—	—	—	—
Current assets	—	—	—	461 693 SEK	—	—	513 524 SEK	—	—	—	—	—	—
Non-current assets	—	—	—	191 815 SEK	—	—	176 990 SEK	—	—	—	—	—	—
Current liabilities	—	—	—	326 557 SEK	—	—	236 569 SEK	—	—	—	—	—	—
Non-current liabilities	—	—	—	155 616 SEK	—	—	29 058 SEK	—	—	—	—	—	—
Revenue	—	—	238 729 SEK	—	—	—	—	—	57 618 SEK	—	—	—	—
Profit (loss)	—	—	388 172 SEK	—	388 172 SEK	—	—	—	172 513 SEK	172 513 SEK	—	—	—
Comprehensive income	0 SEK	0 SEK	388 373 SEK	—	388 172 SEK	201,000 SEK	—	– SEK	167 356 SEK	172 513 SEK	5 157 SEK	– SEK	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Profit (loss) from continuing operations	—	—	322 028 SEK	—	—	—	—	—	168 513 SEK	—	—	—	—
Profit (loss) from discontinued operations	—	—	66 144 SEK	—	—	—	—	—	4 001 SEK	—	—	—	—
Other comprehensive income	—	—	201,000 SEK	—	—	201,000 SEK	—	—	5 157 SEK	—	5 157 SEK	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	—	—	65 402 SEK	—	—	193 994 SEK	—	—	—	—	—	295 180 SEK
Tax expense (income)	—	—	– SEK	—	—	—	—	—	– SEK	—	—	—	—